BiotechTube

Long Acting Reversible Contraception (LARC)

ApprovedTerminated
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception

Trial Timeline

Apr 1, 2016 → Mar 31, 2017

NCT ID
NCT02735551

About Long Acting Reversible Contraception (LARC)

Long Acting Reversible Contraception (LARC) is a approved stage product being developed by Merck for Contraception. The current trial status is terminated. This product is registered under clinical trial identifier NCT02735551. Target conditions include Contraception.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02735551ApprovedTerminated

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
41
Relugolix Combination TherapySumitomo PharmaPhase 3
77
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EEJohnson & JohnsonPhase 1
33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
23
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
oral ulipristal acetateMerckPhase 1
33
Etonogestrel contraceptive implantMerckApproved
85
Rifampin 600 MGMerckApproved
85
Etonogestrel contraceptive implantMerckApproved
85
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
22
Sayana PressPfizerApproved
84
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPfizerPhase 3
76
Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
84

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85